| Novel variants, engineered capsids, and customized vectors are becoming increasingly common. |
|
Progen has been thinking: shouldn't the assay evolve too? That's why Progen is introducing the Pan AAV Capsid Titer Assay (PACTA), which qualifies AAV capsids across multiple serotypes, including novel and engineered variants, in a rapid, no-wash workflow. If you or your team are tired of multiple wash steps and long wait times, this is a good news! |
| A bit more on why PACTA? |
|
• Multi-serotype coverage, including engineered and novel capsids • One assay instead of multiple serotype-specific approaches • Add-and-read workflow with no wash step • Results in less than 60 minutes • Suitable for high-throughput workflows |
| Whether you're working with established serotypes or developing novel capsid variants, PACTA offers a new approach to AAV capsid quantification. |
Come and meet us in Padova
